Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Lymphoma 4Unspecified Adult Solid Tumor, Protocol Specific 3Pancreatic Neoplasms 3Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Acute 1

Interventions

Carboplatin 28Paclitaxel 21Cisplatin 9Topotecan 8Docetaxel 7Taxes 6Oxaliplatin 5Gemcitabine 5Chemotherapy, Adjuvant 5Bevacizumab 5aldesleukin 4Interleukin-12 Subunit p35 4Erlotinib Hydrochloride 4Drug Therapy 4Interleukin-12 3Immunohistochemistry 3Imatinib Mesylate 3Gene Expression Profiling 3Flow Cytometry 3Filgrastim 3Cyclophosphamide 3Amplified Fragment Length Polymorphism Analysis 3trioctyl phosphine oxide 2temsirolimus 2sargramostim 2oregovomab 2ixabepilone 2irofulven 2cediranib 2carboxyamido-triazole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Ovarian Epithelial × 7-hydroxystaurosporine × Clear all
NCT00031681 2013-09-30

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

National Cancer Institute (NCI)

Phase 1 Completed
41 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Esthesioneuroblastoma, Olfactory, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡